Carregant...
Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America
Once-daily fingolimod 0.5 mg (FTY720; Gilenya(®), Novartis Pharma AG, Basel, Switzerland) is a sphingosine 1-phosphate receptor modulator that is approved for the treatment of relapsing multiple sclerosis (MS); currently, this includes approval in 13 Latin American countries. However, despite a well...
Guardat en:
| Publicat a: | Adv Ther |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Healthcare
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4522024/ https://ncbi.nlm.nih.gov/pubmed/26170106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-015-0226-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|